Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs ARWR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARWR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ARWR Overall Winner 6-Pillar Tally: IONS 3 – 3 ARWR Matrix Metrics: IONS 3 – 7 ARWR

As of Nov 16, 2026, Arrowhead Research Corporation (ARWR) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ARWR carries 45.1/100 (HOLD) at $44.57 (111.1x Forward P/E, -33.8% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. ARWR 45.1/100 HOLD), ARWR captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-33.8% vs. -58.8% operating margin) and revenue trajectory (+171.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ARWR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs ARWR
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
ARWR NASDAQ Head-to-Head Winner
Arrowhead Research Corporation
Pharmaceutical Preparations
$44.57
-6.72% 1D
Market Cap $6.7B
TTM Revenue $669M
Forward P/E 111.1x
Beta / 30D Vol 1.34β · 66% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 66.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $55.81 · SMA50: $62.49

6-Pillar Scorecard Institutional Category Breakdown (IONS 3 – 3 ARWR)

Columns: Metric · IONS · ARWR
1. Valuation Multiples IONS
Forward P/E 90.9x 111.1x
Trailing P/E 90.9x 111.1x
PEG Ratio N/M N/M
EV / Revenue 6.2x 11.4x
2. Growth & Scale ARWR
Revenue Growth (YoY) +54.9% +171.0%
Earnings Growth (YoY) -43.7% +9.8%
TTM Revenue (USD) $960M $669M
Market Cap $4.7B $6.7B
3. Profitability & Quality ARWR
Gross Margin 3.0% 100.0%
Operating Margin -58.8% -33.8%
Net Profit Margin -56.9% -47.8%
Return on Equity (ROE) -108.0% -55.2%
4. Balance Sheet & Cash Flow ARWR
Cash Generation (TTM) -$623M -$75M
Cash Flow Margin -64.9% -11.2%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $964M Net Debt (2.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IONS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 59.9% (17th %ile) 69.3% (15th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.38x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (3) vs ARWR (7)
Institutional Metric IONS ARWR Criterion Row Edge
Market Capitalization
Scale
$4.7B $6.7B Larger Scale ARWR
Trailing P/E Ratio
Valuation
90.9x 111.1x Lower Multiple IONS
Forward P/E Ratio
Valuation
90.9x 111.1x Lower Multiple IONS
Revenue Growth (YoY)
Growth
+54.9% +171.0% Higher Growth ARWR
Operating Margin (TTM)
Profitability
-58.8% -33.8% Higher Margin ARWR
Net Profit Margin
Profitability
-56.9% -47.8% Higher Margin ARWR
Return on Equity (ROE)
Capital Efficiency
-108.0% -55.2% Higher ROE ARWR
52-Week Range Position
Momentum
2% ($27–$87) 13% ($37–$95) Stronger Trend ARWR
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.34β · 66% Vol Lower Realized Risk ARWR
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 45.1 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $669M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 11.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$75M ($964M Net Debt (2.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARWR +13.21 pp
IONS: -33.48% · ARWR: -20.27%
3M Horizon ARWR +2.8 pp
IONS: -52.09% · ARWR: -49.29%
6M Horizon ARWR +20.88 pp
IONS: -60.61% · ARWR: -39.73%
1Y Horizon ARWR +67.44 pp
IONS: -59.1% · ARWR: +8.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue ARWR Revenue IONS Op. Margin ARWR Op. Margin Margin Leader
FY2019 $1.12B $170M 32.6% 36.3% ARWR
FY2020 $730M $90M -23.6% -105.9% IONS
FY2021 $810M $140M -3.7% -107.8% IONS
FY2022 $590M $240M -69.8% -73.4% IONS
FY2023 $790M $240M -44.9% -85.2% IONS
FY2024 $710M $0M -67.4% -16927.1% IONS
FY2025 $940M $830M -40.4% 11.9% ARWR
FY2026 N/A $450M N/A -156.9% ARWR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARWR BREAKDOWN
128d in phase · OBV DISTRIBUTION
Current IV 69.3%
IV Percentile 15th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARWR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
ARWR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.7B market capitalization and -33.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs ARWR Key Questions & Quantitative Answers

As of Nov 16, 2026, Arrowhead Research Corporation (ARWR) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ARWR carries 45.1/100 (HOLD) at $44.57 (111.1x Forward P/E, -33.8% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. ARWR 45.1/100 HOLD), ARWR captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-33.8% vs. -58.8% operating margin) and revenue trajectory (+171.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ARWR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARWR leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with ARWR at +171.0% YoY revenue growth and +9.8% YoY earnings growth on $669M TTM revenue (100.0% gross margin, -33.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), IONS cumulative revenue shifted -16.1% while ARWR shifted +164.7%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARWR.

IONS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas ARWR trades at 111.1x Forward P/E, 111.1x Trailing P/E, N/M PEG, and 11.4x EV/Revenue (-11.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus ARWR (-55.2% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, ARWR carries 69.3% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.34β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.